Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

sotrovimab

A neutralizing human monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, sotrovimab specifically targets and binds to an epitope on the SARS-CoV-2 S protein that is shared with SARS-CoV-1, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-SARS-CoV-2 spike protein monoclonal antibody VIR-7831
Code name:GSK 4182136
GSK-4182136
VIR 7831
VIR-7831
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search